PHGE News and Press, Chardan Healthcare Acquisition Corp. From 08/06/25

A look at the top 10 most actives in the United States Safe & Green Holdings Corp. (SGBX) rose 141.6% to $0.4671 on volume of 363,657,432 shares BiomX Inc. (PHGE) rose 19.6% to $0.5201 on volume of 78,449,319 shares LivePerson Inc. (LPSN) rose 39.7% to $1.2404 on volume of 64,019,403 sh...

NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will rep...

2025-07-14 09:38:03 ET DENVER, Colo., Jul 14, 2025 ( 247marketnews.com )- By any measure, July 2025 has become a landmark moment in the ongoing evolution of capital markets. From BioTherapeutics to Blockchain: Sonnet’s Sudden HYPE Turn In perhaps the most head-turning...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results are expected in Q1 2026 Prior Phase 1b/2a efficacy findings demonstrated complet...

Premier research journal article provides validation for BiomX’s phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, updated data demonstrates a further bacteria reduction of 2.7 log₁₀ (app...

NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Sol...

2025-05-15 16:57:17 ET BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call May 15, 2025, 14:00 PM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Yale Jen - Laidlaw & ...

2025-05-15 07:44:19 ET More on BiomX BiomX announces series of financings for aggregate gross proceeds of $12M Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX Read the full article on S...

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exer...

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company ...